This Article Full Text Full Text (PDF) All Versions of this Article: 200206-509OCv1 166/9/1212    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leigh, R. Articles by O'Byrne, P. M. Search for Related Content PubMed PubMed Citation Articles by Leigh, R. Articles by O'Byrne, P. M.

Effects of Montelukast and Budesonide on Airway Responses and Airway Inflammation in Asthma

Asthma Research Group, Firestone Institute for Respiratory Health and Department of Medicine, St. Joseph's Healthcare–McMaster University, Hamilton, Ontario, Canada

Correspondence and requests for reprints should be addressed to Paul M. O'Byrne, M.B., E. J. Moran Campbell Professor, Firestone Institute for Respiratory Health, Room 113, St. Joseph's Hospital, 50 Charlton Avenue East, Hamilton, ON, L8N 4A6 Canada. E-mail: obyrnep{at}mcmaster.ca

Inhaled corticosteroids are effective antiinflammatory therapy for asthma; however, they do not completely abolish allergen-induced airway inflammation. Leukotriene modifiers attenuate both early and late allergen responses and have antiinflammatory properties. We reasoned that treatment with budesonide and montelukast in combination might provide greater antiinflammatory effects than either drug alone, and the purpose of this study was to compare the effects of treatment with budesonide and montelukast, alone or in combination, on outcome variables after allergen inhalation. Ten subjects with asthma with dual responses after allergen inhalation were included in this randomized, double-blind, crossover study. Outcomes included early and late asthmatic responses, and changes in airway responsiveness and sputum eosinophilia, measured before and after challenge. Treatment with montelukast attenuated the maximal early asthmatic response compared with placebo (p < 0.001) and budesonide (p = 0.002). Both budesonide and montelukast, alone and in combination, attenuated the maximal late asthmatic response compared with placebo (p < 0.01). Budesonide and montelukast, alone and in combination, afforded protection against allergen-induced airway hyperresponsiveness (p < 0.05), although the treatment effect of budesonide was greater than that of montelukast (p < 0.05). Treatment with budesonide and montelukast, alone and in combination, also attenuated allergen-induced sputum eosinophilia. Thus, montelukast and budesonide attenuated allergen-induced asthmatic responses, airway hyperresponsiveness, and sputum eosinophilia, although combination treatment did not provide greater antiinflammatory effects than either drug alone.

Key Words: asthma • allergen challenge • airway inflammation • glucocorticosteroids • cysteinyl leukotrienes

This article has been cited by other articles:

				B. E. Davis, C. Illamperuma, G. M. Gauvreau, R. M. Watson, P. M. O'Byrne, F. Deschesnes, L. P. Boulet, and D. W. Cockcroft Single-dose desloratadine and montelukast and allergen-induced late airway responses Eur. Respir. J., June 1, 2009; 33(6): 1302 - 1308. [Abstract] [Full Text] [PDF]

				A. T. Nials and S. Uddin Mouse models of allergic asthma: acute and chronic allergen challenge Dis. Model. Mech., November 1, 2008; 1(4-5): 213 - 220. [Abstract] [Full Text] [PDF]

				D. S. Southam, R. Ellis, J. Wattie, S. Young, and M. D. Inman Budesonide prevents but does not reverse sustained airway hyperresponsiveness in mice Eur. Respir. J., October 1, 2008; 32(4): 970 - 978. [Abstract] [Full Text] [PDF]

				L. B. Fernandes, P. J. Henry, and R. G. Goldie Review: Rho kinase as a therapeutic target in the treatment of asthma and chronic obstructive pulmonary disease Therapeutic Advances in Respiratory Disease, October 1, 2007; 1(1): 25 - 33. [Abstract] [PDF]

				M. Rosewich, M. A. Rose, O. Eickmeier, M. Travaci, R. Kitz, and S. Zielen Montelukast as add-on therapy to {beta}-agonists and late airway response Eur. Respir. J., July 1, 2007; 30(1): 56 - 61. [Abstract] [Full Text] [PDF]

				M. M. Kelly, J. Chakir, D. Vethanayagam, L.-P. Boulet, M. Laviolette, J. Gauldie, and P. M. O'Byrne Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest, September 1, 2006; 130(3): 741 - 753. [Abstract] [Full Text] [PDF]

				C. Bergeron and L.-P. Boulet Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest, April 1, 2006; 129(4): 1068 - 1087. [Abstract] [Full Text] [PDF]

				D. A. Straub, A. Moeller, S. Minocchieri, J. Hamacher, F. H. Sennhauser, G. L. Hall, and J. H. Wildhaber The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma Eur. Respir. J., February 1, 2005; 25(2): 289 - 294. [Abstract] [Full Text] [PDF]

				L Jayaram, E Pizzichini, C Lemiere, S F P Man, A Cartier, F E Hargreave, and M M M Pizzichini Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast Thorax, February 1, 2005; 60(2): 100 - 105. [Abstract] [Full Text] [PDF]

				R. Leigh, R. Ellis, J. Wattie, D. D. Donaldson, and M. D. Inman Is Interleukin-13 Critical in Maintaining Airway Hyperresposiveness in Allergen-challenged Mice? Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 851 - 856. [Abstract] [Full Text] [PDF]

				E. S. Mendes, M. A. Campos, A. Hurtado, and A. Wanner Effect of Montelukast and Fluticasone Propionate on Airway Mucosal Blood Flow in Asthma Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1131 - 1134. [Abstract] [Full Text] [PDF]

				K. Parameswaran, R. Watson, G. M. Gauvreau, R. Sehmi, and P. M. O'Byrne The Effect of Pranlukast on Allergen-induced Bone Marrow Eosinophilopoiesis in Subjects with Asthma Am. J. Respir. Crit. Care Med., April 15, 2004; 169(8): 915 - 920. [Abstract] [Full Text] [PDF]

				J. M. FitzGerald Broadening the Therapeutic Options in Acute Asthma Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 488 - 489. [Full Text] [PDF]

				M. J. Tobin Asthma, Airway Biology, and Nasal Disorders in AJRCCM 2002 Am. J. Respir. Crit. Care Med., February 1, 2003; 167(3): 319 - 332. [Full Text] [PDF]